|
产品描述： Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research |
|
靶点：
hPPARγ:0.93 μM (EC50);mouse PPARγ:0.99 μM (EC50);hPPARδ:43 μM (EC50);hPPARα:100 μM (EC50);mouse PPARα:100 μM (EC50);Ferroptosis;PPAR |
体内研究：
Pioglitazone (oral gavage, 10 or 30 mg/kg, once daily, 14 days) can induce improvements in insulin resistance and diabetes that may be lipocalin-dependent in the liver but not in skeletal muscle. Pioglitazone (oral gavage, 10 mg/kg, once daily, 4 weeks) can significantly reduce body weight (BW), cardiac hypertrophy, elevated blood glucose levels and improve the associated dyslipidemia. |
参考文献：
1. Kuwabara K, et al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose leve 2. Puddu A, et al. Pioglitazone attenuates the detrimental effects of advanced glycation end-products in the pancreatic beta cell line HIT-T15. Regul Pept. 2012 Aug 20;177(1-3):79-84. 3. Kubota N, et al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55. 4. Elrashidy RA, et al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. |
|
溶解性：
DMSO : 40 mg/mL (112.22 mM; ultrasonic and warming and heat to 60°C) |
|
保存条件：
2-8℃ |
配置溶液浓度参考：
|
1mg |
5mg |
10mg |
| 1 mM |
2.545 ml |
12.726 ml |
25.452 ml |
| 5 mM |
0.509 ml |
2.545 ml |
5.09 ml |
| 10 mM |
0.255 ml |
1.273 ml |
2.545 ml |
| 50 mM |
0.051 ml |
0.255 ml |
0.509 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
北京